Patents by Inventor Nicola Anne Burgess

Nicola Anne Burgess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9120860
    Abstract: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: September 1, 2015
    Assignee: UCB Pharma S.A.
    Inventor: Nicola Anne Burgess
  • Publication number: 20130230524
    Abstract: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1.
    Type: Application
    Filed: August 3, 2012
    Publication date: September 5, 2013
    Inventor: Nicola Anne Burgess
  • Patent number: 8263071
    Abstract: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: September 11, 2012
    Assignee: UCB Pharma S.A.
    Inventor: Nicola Anne Burgess
  • Publication number: 20110059088
    Abstract: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCP1 and agents which interact with or modulate the expression or activity of CDCP1 or which modulate the expression of the nucleic acid which codes for CDCP1.
    Type: Application
    Filed: October 14, 2009
    Publication date: March 10, 2011
    Inventor: Nicola Anne Burgess
  • Patent number: 6180384
    Abstract: METPRO02 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing METPRO02 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: September 24, 1998
    Date of Patent: January 30, 2001
    Assignee: SmithKline Beecham plc
    Inventors: Christopher Donald Southan, Nicola Anne Burgess, Conrad Gerald Chapman
  • Patent number: 6165771
    Abstract: The HE2NW40 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HE2NW40 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: December 26, 2000
    Assignee: SmithKline Beecham, P.L.C.
    Inventors: Nicola Anne Burgess, Helen Elizabeth Clinkenbeard, Christopher Donald Southan
  • Patent number: 6100059
    Abstract: HGBAB90 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HGBAB90 polypeptides and polynucleotides in the design of protocols for the treatment of pulmonary emphysema, arthritis, multiple sclerosis, periodontal disease, cystic fibrosis, respiratory disease, thrombosis, cancer, cachexia, angina, glaucoma, inflamatory disorders, osteoporosis, cardiovascular disorders such as hypertension, atherosclerotic disorders such as cardiac infarction, and stroke, asthma, psoriasis, chronic neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's, demyelinating diseases, AIDS immune deficiency, disorders of photoreceptor degeneration, and lens cataract formation, organ transplant rejection, cataracts, restenosis, muscular dystrophy, renal failure, cerebral vasospasm, pancreatitis, and diabetic nephropathy, among others, and diagnostic assays for such conditions.
    Type: Grant
    Filed: April 30, 1998
    Date of Patent: August 8, 2000
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Christopher Donald Southan, Helen Elizabeth Clinkenbeard, Nicola Anne Burgess
  • Patent number: 6090583
    Abstract: HTEGU07 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HTEGU07 polypeptides and polynucleotides in therapy, and diagnostic assays for such.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: July 18, 2000
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Helen Elizabeth Clinkenbeard, Christopher Donald Southan, Nicola Anne Burgess